- Home
- ASRT vs APLT Comparison
ASRT vs APLT Comparison
Compare ASRT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | APLT |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 18.0M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASRT | APLT |
|---|---|---|
| Price | $10.06 | $0.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $45.00 | $1.25 |
| AVG Volume (30 Days) | 30.2K | ★ 9.9M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,354,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $7.71 | $0.10 |
| 52 Week High | $15.15 | $1.50 |
Technical Indicators
Market Signals| Indicator | ASRT | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 98.16 | 25.98 |
| Support Level | $0.61 | $0.10 |
| Resistance Level | $0.75 | $0.13 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.58 | 0.02 |
| Stochastic Oscillator | 94.90 | 7.66 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.